000165000 001__ 165000
000165000 005__ 20251204150238.0
000165000 0247_ $$2doi$$a10.3390/vaccines13101076
000165000 0248_ $$2sideral$$a146058
000165000 037__ $$aART-2025-146058
000165000 041__ $$aeng
000165000 100__ $$aSagrera, Mònica
000165000 245__ $$aEfficacy of a Novel PCV2d and Mycoplasma hyopneumoniae Combined Vaccine in Piglets with High and Low Levels of PCV2 Maternally Derived Antibodies at Vaccination
000165000 260__ $$c2025
000165000 5060_ $$aAccess copy available to the general public$$fUnrestricted
000165000 5203_ $$aBackground/Objectives: Maternally derived antibody (MDA) levels of porcine circovirus 2 (PCV2) may eventually interfere with humoral response and vaccination efficacy. This study aimed to evaluate the efficacy of a ready-to-use PCV2d and Mycoplasma hyopneumoniae combined vaccine in piglets with different PCV2 MDA levels at vaccination in an experimental inoculation with a heterologous viral genotype. Methods: Forty-eight piglets were allocated into vaccinated (V) and non-vaccinated (NV) groups with high (H) and low (L) PCV2 MDA subgroups (H-V, H-NV, L-V, L-NV). At 3 weeks of age, the piglets received either one dose of vaccine or placebo. Five weeks later, all animals were intranasally challenged with a PCV2b inoculum. Body weight was registered at different time points. Blood samples, peripheral blood mononuclear cells and tracheobronchial lymph nodes (TBLN) were collected and used to assess viraemia, viral load, humoral and cellular responses and histological lesions. Results: The V group showed higher PCV2 antibody levels from challenge onwards, along with a lower percentage of viraemic pigs and reduced viral load in serum at 2 and 3 weeks post-challenge (wpc) and in TBLN tissues compared to the NV group. The H-V group had the highest antibody levels post-challenge, showed no detectable viraemia and had a lower overall amount of virus in tissues. The NV group (especially H-NV) exhibited increased levels of IFN-γ, IFN-α and TNF-α post-challenge. Conclusions: The tested vaccine elicited humoral and cellular immune responses and reduced viral presence in serum and tissues, demonstrating efficacy in a PCV2 subclinical infection model despite high MDA levels at the time of vaccination. Understanding both humoral and cellular immune responses according to different MDA levels can help design more effective vaccination strategies against PCV2.
000165000 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000165000 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000165000 700__ $$0(orcid)0000-0001-7106-0068$$aGarza-Moreno, Laura$$uUniversidad de Zaragoza
000165000 700__ $$aCobos, Àlex
000165000 700__ $$aLlorens, Anna Maria
000165000 700__ $$aHuerta, Eva
000165000 700__ $$aPérez, Mónica
000165000 700__ $$aPérez, Diego
000165000 700__ $$aEspigares, David
000165000 700__ $$aSegalés, Joaquim
000165000 700__ $$aSibila, Marina
000165000 7102_ $$11009$$2773$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Sanidad Animal
000165000 773__ $$g13, 10 (2025), 1076 [22 pp.]$$tVaccines$$x2076-393X
000165000 8564_ $$s9019027$$uhttps://zaguan.unizar.es/record/165000/files/texto_completo.pdf$$yVersión publicada
000165000 8564_ $$s2624158$$uhttps://zaguan.unizar.es/record/165000/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000165000 909CO $$ooai:zaguan.unizar.es:165000$$particulos$$pdriver
000165000 951__ $$a2025-12-04-14:39:04
000165000 980__ $$aARTICLE